ADHD

Remote QbCheck testing tracks ADHD treatment progress.

Gus Alva, MD, shares the importance of proper recognition of stuttering among patients.

APSARD 2026 highlights: stimulant safety vs substance use, ADHD in pregnancy, and new nonstimulants.

A new liquid stimulant option promises up to 14-hour ADHD symptom control and flexible dosing for adults and kids who struggle with capsule medication.

Discover insights from Lauren Kenworthy, PhD on treating comorbid ADHD and autism.

The FDA has accepted for priority review an NDA for Otsuka's centanafadine, a novel ADHD treatment.

Douglas Leffa, MD, PhD, shares highlights from a poster at the APSARD conference examining severity and age of diagnosis.

Gerald Maguire, MD, discusses the unmet needs of patients with comorbid ADHD and stuttering.

Tim Wilens, MD, discussed mechanism of action and efficacy of new medications at APSARD Conference.

Timothy Wilens, MD, shares highlights and clinical implications for ADHD from the APSARD Annual Conference.

Review the misperceptions patients and clinicians may have about ADHD diagnosis and treatment.

Experts discuss the complex relationship between ADHD treatment and substance use disorder.

Barry Herman, MD, shares insights on real-world data of online ADHD assessment tool and telepsychiatry.

Clinicians explore the complex relationship between ADHD medication and pregnancy, emphasizing individualized risk assessments for optimal maternal and child health.

A groundbreaking online ADHD assessment shows 78% agreement with clinician evaluations, enhancing access to mental health care for adults.

Allison Baker, MD, shared insights on supporting women before, during, and after pregnancy at the APSARD conference.

Explore key insights on ADHD treatment barriers and the long-term outcomes for adolescents diagnosed with the disorder.

Benjamin E. Yerys, PhD, shares clinical insights on the impact of the comorbidity at the APSARD Conference.

New research reveals midlife ADHD patients exhibit early Alzheimer disease biomarkers.

Poster discusses evidence-based strategies for managing adult ADHD, including medication guidelines and considerations for comorbid conditions.

Poster presented at the APSARD Annual Conference demonstrates the importance of genetic testing in ADHD.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

A look at upcoming presentations at APSARD 2026, January 15-18.

Otsuka Pharmaceutical submits a new drug application for centanafadine for treatment of ADHD, showing significant efficacy across all age groups.

Hormonal fluctuations significantly influence ADHD symptoms in women, highlighting the need for tailored treatments and further research in this area.